Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Total body irradiation (TBI) can induce lethal myelosuppression, due to the sensitivity of proliferating hematopoietic stem/progenitor cells (HSPCs) to ionizing radiation (IR). No effective therapy exists to mitigate the hematologic toxicities of TBI. Here, using selective and structurally distinct small molecule inhibitors of cyclin-dependent kinase 4 (CDK4) and CDK6, we have demonstrated that selective cellular quiescence increases radioresistance of human cell lines in vitro and mice in vivo. Cell lines dependent on CDK4/6 were resistant to IR and other DNA-damaging agents when treated with CDK4/6 inhibitors. In contrast, CDK4/6 inhibitors did not protect cell lines that proliferated independently of CDK4/6 activity. Treatment of wild-type mice with CDK4/6 inhibitors induced reversible pharmacological quiescence (PQ) of early HSPCs but not most other cycling cells in the bone marrow or other tissues. Selective PQ of HSPCs decreased the hematopoietic toxicity of TBI, even when the CDK4/6 inhibitor was administered several hours after TBI. Moreover, PQ at the time of administration of therapeutic IR to mice harboring autochthonous cancers reduced treatment toxicity without compromising the therapeutic tumor response. These results demonstrate an effective method to mitigate the hematopoietic toxicity of IR in mammals, which may be potentially useful after radiological disaster or as an adjuvant to anticancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preclinical studies revealed that CDK4/6 inhibitors protect both cancer cells and normal hematopoietic cells from cytotoxicity induced by IR and DNA damaging agents (125)”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [125]
Experimental — accuracy not yet measuredIn the citing paper
“p21 upregulation actually protected HSCs against IR by limiting IR-induced DNA damage and p53 activation and by promoting HSC cell cycle entry and self-renewing expansion, suggesting that p21 and p16 may have opposite effects on IR-induced HSC senescence.46-48”
From Total body irradiation causes long-term mouse BM injury via induction of HSC premature senescence in an Ink4a- and Arf-independent manner (2014) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clonogenic assay of cells in vitro
Franken, N. A. P., Rodermond, H. M., Stap, J., Haveman, J., & van Bree, C. (2006) · Nature Protocols · doi:10.1038/nprot.2006.339 · Cited by 4,188
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
Kiel, M. J., Yilmaz, Ö. H., Iwashita, T., Yilmaz, O. H., Terhorst, C., & Morrison, S. J. (2005) · Cell · doi:10.1016/j.cell.2005.05.026 · Cited by 3,168
The comet assay: a method to measure DNA damage in individual cells
Olive, P. L., & Banáth, J. P. (2006) · Nature Protocols · doi:10.1038/nprot.2006.5 · Cited by 1,835
Dulić, V., Kaufmann, W. K., Wilson, S. J., Tisty, T. D., Lees, E., Harper, J. W., Elledge, S. J., & Reed, S. I. (1994) · Cell · doi:10.1016/0092-8674(94)90379-4 · Cited by 1,465 · cited 1×
“Prior work in mice has shown that p21CIP, a potent CDK inhibitor and critical mediator of the p53-mediated DNA damage response (29, 30), plays an important role in regulating HSPC quiescence after DNA damage (31).”
A Restriction Point for Control of Normal Animal Cell Proliferation
Pardee, A. B. (1974) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.71.4.1286 · Cited by 1,415
Meijer, L., Borgne, A., Mulner, O., Chong, J. P. J., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J., & Moulinoux, J. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-2-00527.x · Cited by 1,352
Hematopoietic Stem Cell Quiescence Maintained by p21 cip1/waf1
Cheng, T., Rodrigues, N., Shen, H., Yang, Y.-G., Dombkowski, D., Sykes, M., & Scadden, D. T. (2000) · Science · doi:10.1126/science.287.5459.1804 · Cited by 1,339
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · cited 2×
“PD0332991 (13, 14) was provided by Pfizer Inc.”
BackgroundMethodDi Leonardo, A., Linke, S. P., Clarkin, K., & Wahl, G. M. (1994) · Genes & Development · doi:10.1101/gad.8.21.2540 · Cited by 1,215
Cited by
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858
Cyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370
“Although it has been suggested that CDK4/CDK6 inhibitors could be used to induce reversible quiescence, thereby protecting normal cells from radiation-induced toxicit”
BackgroundTargeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
Hematopoietic stem cell niche maintenance during homeostasis and regeneration
Mendelson, A., & Frenette, P. S. (2014) · Nature Medicine · doi:10.1038/nm.3647 · Cited by 792
Targeting CDK4 and CDK6 in cancer
Goel, S., Bergholz, J. S., & Zhao, J. J. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00456-3 · Cited by 531
CDK4 and CDK6 kinases: From basic science to cancer therapy
Fassl, A., Geng, Y., & Sicinski, P. (2022) · Science · doi:10.1126/science.abc1495 · Cited by 464
Targeting cancer with kinase inhibitors
Gross, S., Rahal, R., Stransky, N., Lengauer, C., & Hoeflich, K. P. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76094 · Cited by 444
Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
Álvarez-Fernández, M., & Malumbres, M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.010 · Cited by 390
Molecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment
VanArsdale, T., Boshoff, C., Arndt, K. T., & Abraham, R. T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0816 · Cited by 396
“Preclinical studies showed that CDK4/6 inhibitor pretreatment protects both cancer cells and normal hematopoietic cells from death induced by ionizing radiation and other DNA-damaging agents (38).”
BackgroundTargeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
Finn, R. S., Aleshin, A., & Slamon, D. J. (2016) · Breast Cancer Research · doi:10.1186/s13058-015-0661-5 · Cited by 368
Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy
Prasanna, P. G., Citrin, D. E., Hildesheim, J., Ahmed, M. M., Venkatachalam, S., Riscuta, G., Xi, D., Zheng, G., Deursen, J. V., Goronzy, J., et al. (2021) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djab064 · Cited by 348
Self-citationDeMichele, A., Clark, A. S., Tan, K. S., Heitjan, D. F., Gramlich, K., Gallagher, M., Lal, P., Feldman, M., Zhang, P., Colameco, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2258 · Cited by 343
“The rarity of neutropenic fever/infection suggests that bone marrow progenitors, suppressed during treatment, may still be functional when faced with an infectious challenge, as preclinical studies have suggested (27).”
BackgroundLiauw, S. L., Connell, P. P., & Weichselbaum, R. R. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005148 · Cited by 257
Verma, S., Bartlett, C. H., Schnell, P., DeMichele, A. M., Loi, S., Ro, J., Colleoni, M., Iwata, H., Harbeck, N., Cristofanilli, M., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0097 · Cited by 249
Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy
Roberts, P. J., Bisi, J. E., Strum, J. C., Combest, A. J., Darr, D. B., Usary, J. E., Zamboni, W. C., Wong, K.-K., Perou, C. M., & Sharpless, N. E. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs002 · Cited by 255
“On the basis of the finding that pharmacological quiescence of HSPCs in vivo provides protection from a lethal dose of TBI (8), we sought to determine if pharmacological quiescence would also protect mice from chemotherapy-induced myelosuppression.”
BackgroundMethodResultSelf-citationAn inducible long noncoding RNA amplifies DNA damage signaling
Schmitt, A. M., Garcia, J. T., Hung, T., Flynn, R. A., Shen, Y., Qu, K., Payumo, A. Y., Peres-da-Silva, A., Broz, D. K., Baum, R., et al. (2016) · Nature Genetics · doi:10.1038/ng.3673 · Cited by 239
Cyclin D-CDK4/6 functions in cancer
(2020) · Advances in Cancer Research · doi:10.1016/bs.acr.2020.02.002 · Cited by 218
Genetics and genomics of radiotherapy toxicity: towards prediction
West, C. M., & Barnett, G. C. (2011) · Genome Medicine · doi:10.1186/gm268 · Cited by 204
Size Does Matter: Why Polyploid Tumor Cells are Critical Drug Targets in the War on Cancer
Coward, J., & Harding, A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00123 · Cited by 192
Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy
Knudsen, E. S., Pruitt, S. C., Hershberger, P. A., Witkiewicz, A. K., & Goodrich, D. W. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.03.005 · Cited by 185
Thill, M., & Schmidt, M. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918793326 · Cited by 172
Weiss, J. M., Csoszi, T., Maglakelidze, M., Hoyer, R. J., Beck, J. T., Domine Gomez, M., Lowczak, A., Aljumaily, R., Rocha Lima, C. M., Boccia, R. V., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz278 · Cited by 165
RB1 dual role in proliferation and apoptosis: Cell fate control and implications for cancer therapy
Indovina, P., Pentimalli, F., Casini, N., Vocca, I., & Giordano, A. (2015) · Oncotarget · doi:10.18632/oncotarget.4286 · Cited by 163
Shao, L., Feng, W., Li, H., Gardner, D., Luo, Y., Wang, Y., Liu, L., Meng, A., Sharpless, N. E., & Zhou, D. (2014) · Blood · doi:10.1182/blood-2013-07-515619 · Cited by 165
Self-citationCDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy
McClendon, A. K., Dean, J. L., Rivadeneira, D. B., Yu, J. E., Reed, C. A., Gao, E., Farber, J. L., Force, T., Koch, W. J., & Knudsen, E. S. (2012) · Cell Cycle · doi:10.4161/cc.21127 · Cited by 163
Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion
He, S., Roberts, P. J., Sorrentino, J. A., Bisi, J. E., Storrie-White, H., Tiessen, R. G., Makhuli, K. M., Wargin, W. A., Tadema, H., van Hoogdalem, E.-J., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3986 · Cited by 156
Self-citationOshi, M., Takahashi, H., Tokumaru, Y., Yan, L., Rashid, O. M., Matsuyama, R., Endo, I., & Takabe, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082921 · Cited by 169
Lucke-Wold, B. P., Turner, R. C., Logsdon, A. F., Bailes, J. E., Huber, J. D., & Rosen, C. L. (2014) · Journal of Neurotrauma · doi:10.1089/neu.2013.3303 · Cited by 139
Radioprotective Agents: Strategies and Translational Advances
Kamran, M. Z., Ranjan, A., Kaur, N., Sur, S., & Tandon, V. (2016) · Medicinal Research Reviews · doi:10.1002/med.21386 · Cited by 155
Leveraging the replication stress response to optimize cancer therapy
Cybulla, E., & Vindigni, A. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00518-6 · Cited by 153
Kovatcheva, M., Liu, D. D., Dickson, M. A., Klein, M. E., O’Connor, R., Wilder, F. O., Socci, N. D., Tap, W. D., Schwartz, G. K., Singer, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3364 · Cited by 142
Bisi, J., Sorrentino, J. A., Roberts, P. J., Tavares, F. X., & Strum, J. C. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0775 · Cited by 135
CDK4/6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury
DiRocco, D. P., Bisi, J., Roberts, P., Strum, J., Wong, K.-K., Sharpless, N., & Humphreys, B. D. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00475.2013 · Cited by 126
Self-citationUncoupling p53 Functions in Radiation-Induced Intestinal Damage via PUMA and p21
Leibowitz, B. J., Qiu, W., Liu, H., Cheng, T., Zhang, L., & Yu, J. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0052 · Cited by 132
Hashizume, R., Zhang, A., Mueller, S., Prados, M. D., Lulla, R. R., Goldman, S., Saratsis, A. M., Mazar, A. P., Stegh, A. H., Cheng, S., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now106 · Cited by 123
Geiger, H., Pawar, S. A., Kerschen, E. J., Nattamai, K., Hernández, I., Liang, H., Fernández, J. A., Cancelas, J. A., Ryan, M. A., Kustikova, O. S., et al. (2012) · Nature Medicine · doi:10.1038/nm.2813 · Cited by 118
Self-citationKim, J.-H., Thimmulappa, R. K., Kumar, V., Cui, W., Kumar, S., Kombairaju, P., Zhang, H., Margolick, J., Matsui, W., Macvittie, T., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70812 · Cited by 110
Johnson, N., & Shapiro, G. I. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.525221 · Cited by 120
Palbociclib: an evidence-based review of its potential in the treatment of breast cancer
Traina, T., Cadoo, K., & Gucalp, A. (2014) · Breast Cancer: Targets and Therapy · doi:10.2147/bctt.s46725 · Cited by 107
Pabla, N., Gibson, A. A., Buege, M., Ong, S. S., Li, L., Hu, S., Du, G., Sprowl, J. A., Vasilyeva, A., Janke, L. J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424313112 · Cited by 114
Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer
Witkiewicz, A. K., Chung, S., Brough, R., Vail, P. J., Franco, J., Lord, C. J., & Knudsen, E. S. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.01.022 · Cited by 106
Inhibition of CDK4/6 protects against radiation-induced intestinal injury in mice
Wei, L., Leibowitz, B. J., Wang, X., Epperly, M., Greenberger, J., Zhang, L., & Yu, J. (2016) · Journal of Clinical Investigation · doi:10.1172/jci88410 · Cited by 96
Sammons, S. L., Topping, D. L., & Blackwell, K. (2017) · Current Cancer Drug Targets · doi:10.2174/1568009617666170330120452 · Cited by 96
Preković, S., Schuurman, K. G., Mayayo‐Peralta, I., Manjón, A. G., Buijs, M., Yavuz, S., Wellenstein, M. D., Barrera, A., Monkhorst, K., Huber, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24537-3 · Cited by 96
Leibowitz, B. J., Liang, W., Zhang, L., Ping, X., Epperly, M. W., Greenberger, J. S., Cheng, T., & Yu, J. (2014) · Nature Communications · doi:10.1038/ncomms4494 · Cited by 91
Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells
Blagosklonny, M. V. (2023) · Oncotarget · doi:10.18632/oncotarget.28382 · Cited by 97
Spring, L. M., Bardia, A., & Modi, S. (2016) · PubMed · Cited by 105
Runx1 Loss Minimally Impacts Long-Term Hematopoietic Stem Cells
Cai, X., Gaudet, J., Mangan, J. K., Chen, M. J., Obaldia, M. E. D., Oo, Z. M., Ernst, P., & Speck, N. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028430 · Cited by 92
Metformin as a Radiation Modifier; Implications to Normal Tissue Protection and Tumor Sensitization
Mortezaee, K., Shabeeb, D., Musa, A. E., Najafi, M., & Farhood, B. (2019) · Current Clinical Pharmacology · doi:10.2174/1574884713666181025141559 · Cited by 76
The Evolving Role of Radiation Therapy in the Management of Malignant Melanoma
Khan, N., Khan, M. K., Almasan, A., Singh, A. D., & Macklis, R. M. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.12.071 · Cited by 84
Li, F., Xu, Y., Liu, B., Singh, P. K., Zhao, W., Jin, J., Han, G., Scott, A. W., Dong, X., Huo, L., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1029 · Cited by 80
Self-citationIntestinal stem cell injury and protection during cancer therapy.
Yu, J. (2013) · PubMed · Cited by 99
Radioprotection: smart games with death
Gudkov, A. V., & Komarova, E. A. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43794 · Cited by 75
Targeting CDK4/6 in breast cancer
Shanabag, A., Armand, J., Son, E., & Yang, H. W. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01395-3 · Cited by 80
CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review
Vinciguerra, G. L. R., Sonego, M., Segatto, I., Dall’Acqua, A., Vecchione, A. M., Baldassarre, G., & Belletti, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.891580 · Cited by 82
Epithelial Cell Cycle Behaviour in the Injured Kidney
Moonen, L., D’Haese, P. C., & Vervaet, B. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072038 · Cited by 74
ATR kinase activation in G1 phase facilitates the repair of ionizing radiation-induced DNA damage
Gamper, A. M., Rofougaran, R., Watkins, S. C., Greenberger, J. S., Beumer, J. H., & Bakkenist, C. J. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt833 · Cited by 80
Gogolin, S., Ehemann, V., Becker, G., Brueckner, L. M., Dreidax, D., Bannert, S., Nolte, I. J. A., Savelyeva, L., Bell, E., & Westermann, F. (2013) · Cell Cycle · doi:10.4161/cc.24091 · Cited by 76
Basile, L. A., Ellefson, D., Gluzman-Poltorak, Z., Junes-Gill, K., Mar, V., Mendonca, S., Miller, J. D., Tom, J., Trinh, A., & Gallaher, T. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030434 · Cited by 64
Khan, M. K., & Almasan, A. (2011) · OncoTargets and Therapy · doi:10.2147/ott.s20257 · Cited by 69
Chromatin perturbations during the DNA damage response in higher eukaryotes
Bakkenist, C. J., & Kastan, M. B. (2015) · DNA repair · doi:10.1016/j.dnarep.2015.09.002 · Cited by 71
Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows
Roberts, P. J., Kumarasamy, V. M., Witkiewicz, A. K., & Knudsen, E. S. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1161 · Cited by 66
Radioprotection of normal tissue cells
Maier, P. J., Wenz, F. K., & Herskind, C. (2014) · Strahlentherapie und Onkologie · doi:10.1007/s00066-014-0637-x · Cited by 69
Bisi, J., Sorrentino, J. A., Jordan, J. L., Darr, D. D., Roberts, P. J., Tavares, F. X., & Strum, J. C. (2017) · Oncotarget · doi:10.18632/oncotarget.16216 · Cited by 65
Pleiotrophin mediates hematopoietic regeneration via activation of RAS
Himburg, H. A., Yan, X., Doan, P. L., Quarmyne, M., Micewicz, E., McBride, W., Chao, N. J., Slamon, D. J., & Chute, J. P. (2014) · Journal of Clinical Investigation · doi:10.1172/jci76838 · Cited by 58
Hassanshahi, M., Hassanshahi, A., Khabbazi, S., Su, Y., & Xian, C. J. (2017) · Angiogenesis · doi:10.1007/s10456-017-9577-2 · Cited by 61
Interferon β drives intestinal regeneration after radiation
Leibowitz, B. J., Zhao, G., Liang, W., Ruan, H., Epperly, M. W., Chen, L., Lu, X., Greenberger, J. S., Zhang, L., & Yu, J. (2021) · Science Advances · doi:10.1126/sciadv.abi5253 · Cited by 57
Regulation of tissue‐ and stimulus‐specific cell fate decisions by p53 in vivo
Jackson, J. G., Post, S. M., & Lozano, G. (2011) · The Journal of Pathology · doi:10.1002/path.2783 · Cited by 53
Lin, W., Yuan, N., Wang, Z., Cao, Y. H., Fang, Y., Li, X., Xu, F., Song, L., Wang, J., Zhang, H., et al. (2015) · Scientific Reports · doi:10.1038/srep12362 · Cited by 57
Baek, H. J., Pishvaian, M. J., Tang, Y., Kim, T. H., Yang, S., Zouhairi, M. E., Mendelson, J., Shetty, K., Kallakury, B., Berry, D. L., et al. (2010) · Hepatology · doi:10.1002/hep.24128 · Cited by 51
Lou, X., Zhang, J., Liu, S., Lou, X., & Liao, D. J. (2014) · Cell Cycle · doi:10.4161/cc.29082 · Cited by 51
Sun, W., O'Dwyer, P. J., Finn, R. S., Ruiz-García, A., Shapiro, G. I., Schwartz, G. K., DeMichele, A. M., & Wang, D. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.902 · Cited by 50
Targeting CDK4/6 for Anticancer Therapy
Qi, J., & Ouyang, Z. (2022) · Biomedicines · doi:10.3390/biomedicines10030685 · Cited by 53
CDK4/6 inhibitors in breast cancer
Dukelow, T., Kishan, D., Khasraw, M., & Murphy, C. G. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000249 · Cited by 54
Mangini, N. S., Wesolowski, R., Ramaswamy, B., Lustberg, M. B., & Berger, M. J. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015602273 · Cited by 55
Vaccine Therapy for Heart Failure Targeting the Inflammatory Cytokine Igfbp7
Katoh, M., Nomura, S., Yamada, S., Ito, M., Hayashi, H., Katagiri, M., Heryed, T., Fujiwara, T., Takeda, N., Nishida, M., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.064719 · Cited by 49
Palbociclib for the Treatment of Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Morikawa, A., & Henry, N. L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0390 · Cited by 50
Suppression of luteinizing hormone enhances HSC recovery after hematopoietic injury
Velardi, E., Tsai, J. J., Radtke, S., Cooper, K., Argyropoulos, K. V., Jae-Hung, S., Young, L. F., Lazrak, A., Smith, O. M., Lieberman, S., et al. (2018) · Nature Medicine · doi:10.1038/nm.4470 · Cited by 42
Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice
An, N., Kraft, A. S., & Kang, Y. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-12 · Cited by 52
Guinan, E. C., Barbon, C. M., Kalish, L. A., Parmar, K., Kutok, J. L., Mancuso, C. J., Stoler‐Barak, L., Suter, E. E., Russell, J. D., Palmer, C. D., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003126 · Cited by 46
CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy
Nardone, V., Barbarino, M., Angrisani, A., Correale, P., Pastina, P., Cappabianca, S., Reginelli, A., Mutti, L., Miracco, C., Giannicola, R., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168391 · Cited by 49
Catalase Inhibits Ionizing Radiation-Induced Apoptosis in Hematopoietic Stem and Progenitor Cells
Xiao, X., Luo, H., Vanek, K. N., LaRue, A. C., Schulte, B. A., & Wang, G. Y. (2015) · Stem Cells and Development · doi:10.1089/scd.2014.0402 · Cited by 45
Ayrapetov, M. K., Xu, C., Sun, Y., Zhu, K., Parmar, K., D'Andrea, A. D., & Price, B. D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026064 · Cited by 41
Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility
Martínez, R., Blasina, A., Hallin, J. F., Hu, W., Rymer, I., Fan, J., Hoffman, R. L., Murphy, S., Marx, M. A., Yanochko, G. M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138616 · Cited by 46
Hyperdiploid tumor cells increase phenotypic heterogeneity within Glioblastoma tumors
Donovan, P., Cato, K., Legaie, R., Jayalath, R., Olsson, G., Hall, B. I., Olson, S., Boros, S., Reynolds, B. A., & Harding, A. S. (2014) · Molecular BioSystems · doi:10.1039/c3mb70484j · Cited by 42
Pim1 Serine/Threonine Kinase Regulates the Number and Functions of Murine Hematopoietic Stem Cells
An, N., Lin, Y.-W., Mahajan, S., Kellner, J. N., Wang, Y., Li, Z., Kraft, A. S., & Kang, Y. (2013) · Stem Cells · doi:10.1002/stem.1369 · Cited by 42
Self-citationRole of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment
Parylo, S., Vennepureddy, A., Dhar, V., Patibandla, P., & Sokoloff, A. (2018) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155218770904 · Cited by 42
Kumarasamy, V. M., Ruiz, A., Nambiar, R., Witkiewicz, A. K., & Knudsen, E. S. (2019) · Oncogene · doi:10.1038/s41388-019-1102-1 · Cited by 41
Searching for targets for the systemic therapy of mesothelioma
Stahel, R. A., Weder, W., Felley‐Bosco, E., Petrausch, U., Fontecedro, A. C., Schmitt-Opitz, I., & Peters, S. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv101 · Cited by 40
Lee, C., Oh, P., Xu, E. S., Ma, Y., Kim, Y., Daniel, A. R., & Kirsch, D. G. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.07.192 · Cited by 41
Progression-free survival (PFS) and toxicities of palbociclib in a geriatric population
Clifton, K., Yi, M., Kimmel, J., Litton, J. K., Tripathy, D., & Karuturi, M. S. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05181-4 · Cited by 36
Blocking cell cycle progression through CDK4/6 protects against chronic kidney disease
Osaki, Y., Manolopoulou, M., Ivanova, A. V., Vartanian, N., Mignemi, M. P., Kern, J., Chen, J., Yang, H., Fogo, A. B., Zhang, M., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.158754 · Cited by 36
Patwardhan, R. S., Sharma, D., Checker, R., & Sandur, S. K. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.11.004 · Cited by 34
Kang, J. W., Zhan, Z., Ji, G., Sang, Y., Zhou, D., Li, Y., Feng, H., & Cheng, T. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00510-w · Cited by 33
Self-citationIwasaki, D., Yamamoto, Y., Murao, N., Oyama, A., Funayama, E., & Furukawa, H. (2016) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000002887 · Cited by 33
Wang, B., Tanaka, K., Morita, A., Ninomiya, Y., Maruyama, K., Fujita, K., Hosoi, Y., & Nenoi, M. (2013) · Journal of Radiation Research · doi:10.1093/jrr/rrs140 · Cited by 33
Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside
Meattini, I., Livi, L., Lorito, N., Becherini, C., Bacci, M., Visani, L., Fozza, A., Belgioia, L., Loi, M., Mangoni, M., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102417 · Cited by 31
Focal adhesion kinase antagonizes doxorubicin cardiotoxicity via p21Cip1
Cheng, Z., DiMichele, L. A., Rojas, M., Vaziri, C., Mack, C. P., & Taylor, J. M. (2013) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2013.12.002 · Cited by 30
Emerging targets for radioprotection and radiosensitization in radiotherapy
Kumar, S., Singh, R. K., & Meena, R. (2016) · Tumor Biology · doi:10.1007/s13277-016-5117-8 · Cited by 31
Immune mechanisms in the different phases of acute tubular necrosis
Kundert, F., Platen, L., Iwakura, T., Zhao, Z., Marschner, J. A., & Anders, H. (2018) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.2018.37.3.185 · Cited by 30
Metadata
- Authors
- Johnson, S. M., Torrice, C. D., Bell, J. F., Monahan, K. B., Jiang, Q., Wang, Y., Ramsey, M. R., Jin, J., Wong, K.-K., Su, L., Zhou, D., & Sharpless, N. E.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Medical University of South Carolina (US)
- Harvard University (US)
- Corresponding author
- Sharpless, Norman E.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2010-07-01
- Volume
- 120
- Issue
- 7
- Pages
- 2528-2536
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC2898594
- OpenAlex
- W1967829518
- Cited by
- 168
- References
- 66
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 6 · 2023: 4 · 2022: 8 · 2021: 12 · 2020: 10 · 2019: 10 · 2018: 10 · 2017: 8 · 2016: 15 · 2015: 16 · 2014: 14 · 2013: 14 · 2012: 7
- FWCI
- 10.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Institutes of Health (5r01ag024379-15)
- National Institute on Aging (R01-AG024379, F30AG034806)
- National Cancer Institute (R01CA122023, R01CA122794, R01CA086860)
- National Institute of General Medical Sciences (GM008581, T32GM008719, T32GM008581)
- National Institute of Allergy and Infectious Diseases (R01AI080421, R01AI077454, R01AI080432)
- National Institute of Environmental Health Sciences (P30ES010126)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Effects of Radiation Exposure
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
- Keywords
- CDK4/6 inhibitors, total body irradiation, hematopoietic stem and progenitor cells, quiescent cells, radioresistance (biology), myelosuppression, ionizing radiation, DNA-damaging agents, bone marrow, autochthonous tumors, cancer therapy
- MeSH terms
- Animals, Antineoplastic Agents, Cell Cycle, Cell Line, Hematopoietic Stem Cells, Mice, Inbred C3H, Mice, Inbred C57BL, Radiation, Mice, Knockout, Cyclin-Dependent Kinase Inhibitor p18, Cyclin-Dependent Kinase 4, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.